{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T23:50:28Z","timestamp":1767916228644,"version":"3.49.0"},"reference-count":4,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T00:00:00Z","timestamp":1542067200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s00277-018-3552-x","type":"journal-article","created":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T20:54:50Z","timestamp":1542056090000},"page":"1509-1510","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Progressive multifocal leukoencephalopathy developing after obinutuzumab treatment for chronic lymphocytic leukemia"],"prefix":"10.1007","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9695-9288","authenticated-orcid":false,"given":"Vlatko","family":"Pejsa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marko","family":"Lucijanic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeljko","family":"Jonjic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeljko","family":"Prka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gorana","family":"Vukorepa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,11,13]]},"reference":[{"issue":"12","key":"3552_CR1","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","volume":"370","author":"V Goede","year":"2014","unstructured":"Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy MS, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer KA, Stilgenbauer S, Dohner H, Langerak AW, Ritgen M, Kneba M, Asikanius E, Humphrey K, Wenger M, Hallek M (2014) Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 370(12):1101\u20131110. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1313984","journal-title":"N Engl J Med"},{"issue":"8","key":"3552_CR2","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1080\/14740338.2016.1198775","volume":"15","author":"DW Raisch","year":"2016","unstructured":"Raisch DW, Rafi JA, Chen C, Bennett CL (2016) Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA\u2019s adverse event reporting system. Expert Opin Drug Saf 15(8):1003\u20131011. \n                    https:\/\/doi.org\/10.1080\/14740338.2016.1198775","journal-title":"Expert Opin Drug Saf"},{"issue":"15","key":"3552_CR3","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.2217\/fon-2016-0084","volume":"12","author":"J Edelmann","year":"2016","unstructured":"Edelmann J, Gribben JG (2016) Obinutuzumab for the treatment of indolent lymphoma. Future Oncol 12(15):1769\u20131781. \n                    https:\/\/doi.org\/10.2217\/fon-2016-0084","journal-title":"Future Oncol"},{"issue":"2","key":"3552_CR4","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1177\/1756285612470401","volume":"6","author":"O Fernandez","year":"2013","unstructured":"Fernandez O (2013) Best practice in the use of natalizumab in multiple sclerosis. Ther Adv Neurol Disord 6(2):69\u201379. \n                    https:\/\/doi.org\/10.1177\/1756285612470401","journal-title":"Ther Adv Neurol Disord"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3552-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-018-3552-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3552-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T19:14:52Z","timestamp":1573586092000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-018-3552-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,13]]},"references-count":4,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["3552"],"URL":"https:\/\/doi.org\/10.1007\/s00277-018-3552-x","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,13]]},"assertion":[{"value":"24 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"VP, ML, and ZP have received a speaker honorarium from Roche. Other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}},{"value":"Patient\u2019s family provided informed consent for publishing.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}